Ig Vena

Human normal immunoglobulin, the active ingredient in Ig Vena, is an immunoglobulin presented as a solution for injection for intravenous use. It treats primary and secondary immunodeficiency diseases, idiopathic thrombocytopenic purpura, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy.

GNH USA supplies Ig Vena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ig Vena, a human normal immunoglobulin, provides passive immunity for disorders involving antibody deficiency or immune dysregulation. - Primary immunodeficiency diseases: restores deficient IgG levels to reduce infection frequency. - Secondary immunodeficiency: supplements antibodies in patients with acquired immune deficits, such as after chemotherapy. - Idiopathic thrombocytopenic purpura: modulates immune response to increase platelet count. - Kawasaki disease: reduces inflammation and coronary artery complications in the acute phase. - Chronic inflammatory demyelinating polyneuropathy: attenuates autoimmune attack on peripheral nerves.

Ig Vena may be associated with infusion‑related reactions and other adverse events.

Common Side Effects: - Headache: mild to moderate pain often occurring during or shortly after infusion. - Fever and chills: transient rise in body temperature and shivering. - Nausea: occasional upset stomach or feeling of queasiness. - Fatigue: temporary tiredness following administration.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: clot formation that can affect veins or arteries. - Renal failure: impaired kidney function, especially with high infusion volumes. - Aseptic meningitis: inflammation of the meninges without infection.

When using Ig Vena, clinicians should observe several safety measures. - Screen for IgA deficiency: patients with anti‑IgA antibodies may develop severe reactions. - Monitor renal function: high‑volume infusions can stress kidneys. - Assess thrombotic risk: consider prophylaxis in patients with known risk factors. - Avoid use in patients with known hypersensitivity to immunoglobulin products. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ig Vena can interact with several medications; awareness of the level of interaction helps guide monitoring.

Major Interactions (Avoid): - Live vaccines: concurrent use may reduce vaccine efficacy and increase infection risk. - Cytotoxic chemotherapy: may heighten renal toxicity when combined. - Anticoagulants: can potentiate bleeding risk due to volume load.

Moderate Interactions (Monitor Closely): - Diuretics: monitor fluid balance and electrolytes during infusion. - ACE inhibitors: watch for hypotension, especially with rapid infusion rates. - Rituximab: may alter immunoglobulin levels and affect therapeutic response.